Serum Erythropoietin Measurement in the Evaluation of Polycythemia and Anemia

Indications for Testing

Use in Chronic Kidney Disease (CKD)

Predictive Role in Myelodysplastic Syndromes (MDS)

Interpretation of Low EPO Values

Common Diagnostic Pitfalls

All statements are derived from peer‑reviewed sources and each bullet includes the corresponding citation identifier.

Erythropoietin Level Elevation Causes

Hypoxia-Driven Causes

• The American College of Physicians suggests that central hypoxic processes, including right-to-left cardiopulmonary vascular shunts, high-altitude habitation, carbon monoxide poisoning, and hypoventilation syndromes, can lead to elevated erythropoietin (EPO) levels 5, 6
• Peripheral hypoxic processes, such as renal artery stenosis, high oxygen-affinity hemoglobinopathies, and 2,3-Diphosphoglycerate mutase deficiency, can also cause elevated EPO levels 5, 7

Hypoxia-Independent Pathologic EPO Production

• The National Comprehensive Cancer Network recommends that malignant tumors, including hepatocellular carcinoma, renal cell cancer, cerebellar hemangioblastoma, and parathyroid carcinoma, be evaluated for ectopic EPO production 6, 8, 7
• Nonmalignant conditions, such as uterine leiomyomas, renal cysts and polycystic kidney disease, pheochromocytoma, and meningioma, can also produce EPO autonomously 6, 8, 7

Congenital Disorders with Elevated EPO

• The European Hematology Association notes that Chuvash polycythemia is a congenital disorder with abnormal oxygen homeostasis, resulting in abnormally elevated EPO production 6, 7

Diagnostic Considerations

• The Mayo Clinic recommends that serum EPO levels >500 mU/mL indicate erythropoietin resistance, making exogenous EPO therapy unlikely to be effective 9
• A normal EPO level does not exclude secondary polycythemia, and evaluation for cardiopulmonary disease, smoking history, and oxygen saturation is necessary even when EPO is not elevated 6, 8

Normal Erythropoietin Levels and Clinical Significance

Reference Ranges and Clinical Interpretation

• Normal endogenous erythropoietin levels in healthy adults range between 10 IU/L and 30 IU/L (or 10-30 mU/mL) 10
• EPO levels >500 mU/mL indicate erythropoietin resistance, making exogenous EPO therapy less likely to be effective 10, 11
• EPO levels ≤500 mU/mL in anemic patients may predict a better response to erythropoiesis-stimulating agents (ESAs) 12, 13

Pitfalls in EPO Level Interpretation

• Measurement of EPO levels in patients with impaired kidney function and normochromic, normocytic anemia is rarely helpful for clinical decision-making or guiding EPO therapy, according to the American Journal of Kidney Diseases 14